Cancer Advisor | One Day MD

Introduction: Why This Debate Went Viral In 2026, a high-profile medical dispute spread across X (Twitter) and Substack involving two physicians with opposing views on the use of benzimidazole drugs —notably fenbendazole (veterinary dewormer) and mebendazole (human antiparasitic) —as potential cancer treatments. Naturopathic physician Dr. Colleen Huber, from her Arizona clinic, warned against using mebendazole and fenbendazole for cancer, calling it a risky fad that damages essential cell structures. Former physician William Makis countered with mebendazole's history since 1971, FDA approval for children as young as one, and his experience treating over 9,000 patients—though unverified. While lab studies show anticancer promise by disrupting tumor growth like some chemotherapies, human evidence is limited, fenbendazole remains veterinary-only with liver risks, and experts recommend sticking to proven treatments under medical guidance. ( X.com ) ...

White Paper · Integrative Oncology · June 2026 ✎ OneDayMD Editorial Team  Last Updated: September 2026   Medically Reviewed by: OneDayMD Editorial Team  DOI-equivalent: onedaymd.com/fenbendazole-cancer-protocol-2026 Abstract Background: Cancer remains the second leading cause of death globally. Advanced-stage disease carries poor prognosis, and a significant proportion of patients either fail conventional therapy or seek adjunctive options. Over the past decade, the repurposed antiparasitic agents fenbendazole, ivermectin, and mebendazole have attracted increasing attention for potential anti-neoplastic activity based on preclinical and emerging clinical data. Objective: To synthesise (1) a systematic case-series compilation of 760+ patient-reported outcomes across 31 cancer subtypes involving antiparasitic repurposed drugs; (2) an evidence-based 7-layer Metabolic Cancer Fram...